FAQ on Calidi Biotherapeutics Inc.'s Investor Webinar and RedTail Platform
Summary
Calidi Biotherapeutics Inc. is hosting an investor webinar on July 24, 2025, to showcase its RedTail platform and oncology advancements, highlighting preclinical data on CLD-401 and progress toward an IND filing.
What is the main purpose of Calidi Biotherapeutics Inc.’s investor webinar?
The webinar aims to showcase Calidi’s RedTail platform, a systemically delivered viral therapy designed to treat metastatic tumors, and discuss preclinical data on lead candidate CLD-401, along with progress toward an IND filing and strategic pharma partnerships.
When and where is the investor webinar taking place?
The investor webinar is scheduled for July 24, 2025, at 4:15 p.m. ET. Details on how to access the webinar can be found in the full press release at https://ibn.fm/zIp8d.
Who is leading the investor webinar?
The webinar will be led by Calidi Biotherapeutics Inc.’s CEO, Eric Poma, Ph.D.
What is the RedTail platform?
The RedTail platform is a systemically delivered viral therapy designed to treat metastatic tumors by evading immune detection, as part of Calidi Biotherapeutics Inc.’s efforts in developing targeted genetic medicine therapies.
What preclinical data will be showcased during the webinar?
Preclinical data on lead candidate CLD-401, which showed tumor elimination and immune memory activation, will be highlighted during the webinar.
What are the next steps for Calidi Biotherapeutics Inc.?
The company is progressing toward an IND filing for its lead candidate and pursuing strategic pharma partnerships to support commercialization of its therapies.
How can I learn more about Calidi Biotherapeutics Inc.?
For more information, visit the company’s website at www.calidibio.com or the latest news and updates relating to CLDI in the company’s newsroom at https://ibn.fm/CLDI.
What is the significance of the RedTail platform in oncology?
The RedTail platform represents a novel approach in immuno-oncology, utilizing stem cell-based platforms to deliver oncolytic viruses directly to tumors, potentially enhancing efficacy and improving patient safety in treating metastatic diseases.
Will there be an opportunity to ask questions during the webinar?
Yes, a Q&A session will follow the presentation, allowing participants to engage with the CEO and possibly other members of the Calidi Biotherapeutics Inc. team.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 113902